X
Upload your Marketing & Sales content on your company Virtual Booth, click HERE.
Details:
VIVJOA® (oteseconazole) is an azole antifungal and designed to selectively inhibit fungal CYP51, which is indicated for the treatment of severe vulvovaginal candidiasis (VVC).
Lead Product(s): Oteseconazole
Therapeutic Area: Infections and Infectious Diseases Product Name: Vivjoa
Highest Development Status: ApprovedProduct Type: Small molecule
Recipient: Mycovia Pharmaceuticals
Deal Size: Not Applicable Upfront Cash: Not Applicable
Deal Type: Not Applicable August 21, 2023
Details:
Apatinib (rivoceranib) is a tyrosine kinase inhibitor that selectively inhibits the VEGFR-2 in combination with AiRuiKa (camrelizumab) a humanized mAb targeting the PD-1 receptor, is being investigated for unresectable hepatocellular carcinoma.
Lead Product(s): Rivoceranib,Camrelizumab
Therapeutic Area: Oncology Product Name: Apatinib
Highest Development Status: Phase IIIProduct Type: Small molecule
Recipient: Elevar Therapeutics
Deal Size: Not Applicable Upfront Cash: Not Applicable
Deal Type: Not Applicable May 17, 2023
Details:
Camrelizumab (SHR-1210) is a humanized monoclonal antibody targeting the programmed death-1 (PD-1) receptor. Blockade of the PD-1/PD-L1 signaling pathway is a therapeutic strategy showing success in a wide variety of solid and hematological cancers.
Lead Product(s): Camrelizumab,Rivoceranib
Therapeutic Area: Oncology Product Name: SHR-1210
Highest Development Status: Phase IIIProduct Type: Large molecule
Partner/Sponsor/Collaborator: Not Applicable
Deal Size: Not Applicable Upfront Cash: Not Applicable
Deal Type: Not Applicable September 10, 2022
Details:
Camrelizumab (SHR-1210) is a humanized monoclonal antibody targeting the programmed death-1 (PD-1) receptor. Blockade of the PD-1/PD-L1 signaling pathway is a therapeutic strategy showing success in a wide variety of solid and hematological cancers.
Lead Product(s): Camrelizumab,Rivoceranib
Therapeutic Area: Oncology Product Name: SHR-1210
Highest Development Status: Phase IIIProduct Type: Large molecule
Recipient: Elevar Therapeutics
Deal Size: Not Applicable Upfront Cash: Not Applicable
Deal Type: Not Applicable September 07, 2022
Details:
CStone granted the exclusive rights to Hengrui for research, development, registration, manufacturing, and commercialization of anti-CTLA-4 mAb CS1002 in the Greater China region.
Lead Product(s): CS1002,CS1003
Therapeutic Area: Oncology Product Name: CS1002
Highest Development Status: Phase IProduct Type: Large molecule
Recipient: CStone Pharmaceuticals
Deal Size: $200.0 million Upfront Cash: Undisclosed
Deal Type: Partnership November 21, 2021
Details:
Yingli Pharma will grant Hengrui Medicine joint development rights and exclusive commercialization rights of PI3kδ inhibitor YY-20394 in Greater China.
Lead Product(s): Linperlisib
Therapeutic Area: Oncology Product Name: YY-20394
Highest Development Status: Phase IIIProduct Type: Small molecule
Recipient: Shanghai Yingli Pharmaceutical
Deal Size: $20.0 million Upfront Cash: Undisclosed
Deal Type: Agreement February 08, 2021
FULL SCREEN VIEW Click here to open all results in a new tab [this preview display 10 results] 
Market Place
